Provided by Tiger Trade Technology Pte. Ltd.

Citius Pharmaceuticals, Inc.

0.5719
-0.0283-4.72%
Volume:275.61K
Turnover:159.92K
Market Cap:15.70M
PE:-0.27
High:0.6100
Open:0.6100
Low:0.5700
Close:0.6002
52wk High:2.19
52wk Low:0.4687
Shares:27.45M
Float Shares:26.96M
Volume Ratio:0.35
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1219
EPS(LYR):-3.3830
ROE:-81.09%
ROA:-26.57%
PB:0.24
PE(LYR):-0.17

Loading ...

Citius Pharma Wins NASDAQ Extension to Regain $1 Minimum Bid by Feb. 8, 2027

Reuters
·
Aug 22

Citius Oncology Files Form 3 for Director Jonathan Peri

Reuters
·
Aug 15

Citius Oncology Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate

Benzinga Earnings
·
Aug 15

Citius Oncology FY26 Q3 Net Loss Widens to $8.9 Million; Revenue Rises to $1.5 Million

Reuters
·
Aug 15

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 15

Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 15

Citius Oncology Appoints Jonathan Peri as Independent Director, Expands Board to Nine Members

Reuters
·
Aug 12

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

THOMSON REUTERS
·
Aug 12

Citius Oncology Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Citius Pharma Subsidiary Citius Oncology Says New Lymphir Institutional Accounts Jump 78% Q/Q

Reuters
·
Aug 05

Citius Oncology Reports Strong Commercial Momentum for Its Cancer Treatment

THOMSON REUTERS
·
Aug 05

Citius Oncology provides update on commercial launch of Lymphir

TIPRANKS
·
Jul 21

Citius Pharma Publishes Corporate Deck Spotlighting Lymphir Launch, Mino-lok Phase 3, Halo-lido Program

Reuters
·
Jul 08

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

TIPRANKS
·
Jun 01

Citius Oncology highlights Phase 1 study data for LYMPHIR-pembrolizumab combo in recurrent gynecologic cancers

Reuters
·
Jun 01

Citius Oncology shareholders OK stock issuance tied to USD 25 million loan conversion option

Reuters
·
May 30

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Simply Wall St.
·
May 28

Citius Oncology to present Phase 1 LYMPHIR-pembrolizumab combo data at ASCO 2026

Reuters
·
May 26

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

TIPRANKS
·
May 23